Abstract The purpose of this study was to examine the safety and efficacy of the Frontrunner XP CTO (chronic total occlusion) Catheter (Cordis) for recanalization of long femoropopliteal artery occlusions. A Frontrunner catheter was used to treat 26 CTOs in SFA after guidewire failure (68.3 ± 8.8 years). Sixty-seven percent of patients had severe claudication. Critical lower limb ischemia with rest pain or minor tissue loss was present in three and eight patients, respectively. All the lesions were considered complex (TASC B, C, and D); 68% of the lesions were heavily calcified. The mean lesion length was 17.6 cm (range, 10-42 cm). The initial attempt to cross the occlusion with the CTO guidewire V18 was unsuccessful in 26 of 76 limbs (34.26%). A secondary attempt using the Frontrunner catheter (crossover approach, 27%; antegrade, 73%) performed in all 26 failed cases was successful in 17 limbs (65.38%), increasing the technical success rate to 88.12%. The main reasons for failure with the Frontrunner were inability to cross the lesion due to heavy calcification (six of nine) and inability to re-enter the true lumen after subintimal passage of the occluded segment (three of nine). The mean fluoroscopy time was 22.9 min. Minor complications included one distal extension of the dissection with involvement of the first popliteal segment and one perforation in the occluded segment. No major complications were seen. In conclusion, recanalization with the Frontrunner CTO catheter is a simple and safe method with a high technical success rate in the endovascular treatment of long superficial femoral artery occlusions and should be an alternative method after guidewire failure.
Introduction
Endovascular therapy for complex lesions of the superficial femoral and popliteal artery remains controversial. The TransAtlantic Inter-Society Consensus (TASC; 2000 and 2007) document was recently published to propose treatment strategies and recommendations for the management of peripheral arterial disease. Per recommendation, TASC A lesions are most suitable for an endovascular procedure, whereas surgery is recommended primarily for TASC D lesions. The TASC document clearly states that more evidence is needed to make firm recommendations about the role of percutaneous transluminal angioplasty (PTA) for TASC B and C lesions [1] [2] [3] .
On the other hand, long femoropopliteal (FP) arterial occlusions continue to pose an endovascular challenge, in part because a guidewire cannot always be passed through the lesion. Van der Heijden et al. reported that percutaneous recanalization of long chronic total occlusion (CTO) of the superficial femoral artery (SFA) with traditional methods has moderate success rates of 40% to 60%, depending on lesion length, calcification, operator experience, and runoff vessel status [4] . This study was published 16 years ago. In light of new advances in endovascular technique, combined with recent advances in wire technology and adjunctive devices, this information is now outdated.
During the same period Bolia et al. introduced the technique of subintimal recanalization [5, 6] . Since then a modification of this technique has allowed treatment of long occlusions not amenable to PTA and has broadened the indications for endovascular management. Many studies have shown relatively high technical success rates for this technique, ranging from 74 to 92% [7] [8] [9] [10] . As to the durability of the subintimally created channels, there is ongoing controversy. Primary patency rates at 12 months varied among previous studies between 22 and 74% [11] [12] [13] [14] . However more randomized trials will be necessary to provide more definitive data regarding this technology for patients with claudication. In the excitement of new technology, interventional physicians have pursued over the last years multiple new methods of revascularization liked excisional and ablative atherectomy. Although these new adjunctive devices may improve the technical success of intraluminal traverse of these complex lesions, most of these techniques have yet failed to show superior long-term efficacy [15] [16] [17] [18] [19] [20] [21] , as the phenomenon of intimal hyperplasia may be even more pronounced after atherectomy than after PTA and stent implantation.
However, only limited data are available for controlled blunt microdissection for PTA of chronic total occlusions in peripheral arteries [22] [23] [24] . The purpose of this prospective study was to determine the safety and efficacy of a new CTO device, the Frontrunner XP CTO Catheter (FR-XP; Cordis Corp., a Johnson & Johnson Co., Miami, FL, USA), for recanalization of long FP arterial occlusions after guidewire failure. The Frontrunner catheter is a blunt microdissection device that takes advantage of the elastic properties of adventitia versus inelastic properties of fibrocalcific plaque to create fracture planes. This technique may be advantageous in penetrating hard fibrous caps and creating a passage through the CTO.
Materials and Methods

Patient Selection and Study Population
The study was performed as a prospective, nonrandomized single-center trial and was approved by the local institutional review board. From January 2007 to February 2008, 76 patients with angiographically documented chronic FP occlusions ([10 cm) and at least a 6-month history of symptoms presented for endovascular therapy. Standard guidewire recanalization failed due to highly calcified lesions in a total of 26 patients (mean age, 68.3 ± 8.8 years; range, 50 to 86 years; gender, 14 men and 12 women) who were then treated with the FR-XP catheter. Sixty-seven percent of these patients had severe claudication (Fontaine class IIb). Critical lower limb ischemia with rest pain or minor tissue loss was present in three and eight patients, respectively. Diabetes was present in 30%, and 20% had end-stage renal disease. All lesions were considered complex (types B, C, and D; TASC 2007); 68% of the lesions were heavily calcified and 38% were located at a bifurcation beginning with a very short stump,\5 cm. The mean lesion length was 17.26 cm (range, 10 to 42 cm) and five occlusions involved the PI segment of the popliteal artery. All characteristics of the patients and FP occlusions are summarized in Tables 1 and 2 , respectively.
The Frontrunner XP CTO Catheter (Cordis Corp.)
The FR-XP catheter ( Fig. 1 ) was originally designed for use in coronary arteries. More recently, the device has been increasingly used to facilitate guidewire placement across peripheral CTOs. The FR-XP catheter is used in combination with the Frontrunner Micro Guide Catheter (MCG), which provides additional support for the device and acts as a conduit for more rapid wire exchange after crossing of the CTO. The Frontrunner catheter consists of a handle assembly with an integral rotator and a flush port for internal device flushing, a proximal braided shaft for push and torque control, and a flexible distal shaft which may be manually shaped. The radiopaque blunt-shaped distal actuating tip is comprised of a set of bilateral hinged TC total cholesterol; BMI body mass index; ABI ankle-brachial index pieces. The device has a 6-Fr profile; blunt microdissection creates an intraluminal pathway through a CTO, enabling guidewire placement in the distal true lumen. The catheter does not have a guidewire lumen.
Micro Guide Catheter (Cordis Corp.)
The MCG with a hydrophilic coating ( Fig. 2) is recommended for use with the FR-XP and is designed to provide additional support to the distal portion of the FR-XP. After crossing the occlusion with the FR-XP, the MGC may be used to facilitate placement of a guidewire across the lesion.
Procedure
For procedure planning, evaluation of anatomic and hemodynamic factors of disease severity and quality of distal runoff MR or MSCT angiography (Magnetom Avanto 1.5T and Somatom Sensation 16; Siemens, Erlangen, Germany) using adapted protocols was performed in all patients (Fig. 3A, B ). Clinical status of peripheral vascular disease was determined by documentation of clinical symptoms and measurements of the Doppler ankle-brachial index (ABI) at rest. Formal written consent was obtained from all patients prior to the procedure. In all patients, intraluminal recanalization via the femoral approach was the intended procedure. In the majority of cases, due to a sufficient proximal SFA stump and large-caliber common femoral artery (CFA), the primary recanalization procedure was attempted by an antegrade approach (antegrade, 73%; crossover approach, 27%), starting with ipsilateral antegrade puncture of the CFA and introduction of a short 6-Fr hemostatic sheath (Radiofocus Introducer II; Terumo, Tokyo). The antegrade approach was also used in the case of a short stump (\5 cm) when difficult iliac anatomy precluded a crossover approach. It is the policy of our department to treat patients presenting with intermittent claudication by intraluminal angioplasty and stenting. It is also well known that recanalizing such an occlusion via the standard intraluminal approach with a normal 0.035-in. hydrophilic guidewire is often unsuccessful because the guidewire frequently enters the subintimal space, a fact which, in addition, makes the use of the FR-XP afterward unfeasible. Therefore following an angiogram and acquisition of a roadmap, crossing of the CTO was attempted, always using an 0.018-in. CTO guidewire (V18 Control Wire; Boston Scientific, Natick, MA, USA) supported by a 4-or 5-Fr multipurpose guiding catheter (Cordis Endovascular, Warren, NJ, USA) placed in the origin of the occlusion. If three to five attempts to transverse the occlusion with the guidewire were unsuccessful, the FR-XP was employed. After activation (jaw opening and closing) and passage through the proximal cap of the CTO, the Frontrunner microtome-supported by the MCG-was navigated forward through the occluded segments with its jaws closed. Then, to create a larger microdissection canal, the FR-XP was repeatedly pulled back with ''open jaw.'' In some cases, due to heavily calcification, further jaw activations were necessary in stepwise fashion through the occlusion. Fluoroscopic roadmapping was used throughout to verify alignment of catheters with the vessel lumen. After initial FR-XP passage, the MGC was advanced into the distal popliteal artery and used for wire introduction. Balloon angioplasty was performed and the vessel was dilated from the distal to the proximal segment. Adjunctive stenting with self-expanding nitinol stents was performed in all cases. Final angiography, including evaluation of the treatment site and of the lower limb runoff, was done before the hemostatic sheath was removed.
In the case of FR-XP failure percutaneous intentional extraluminal recanalization (PIER) with an angled 0.035-in. hydrophilic guidewire was performed. Follow-up with documentation of clinical symptoms, assessment of Rutherford clinical stage of peripheral vascular disease [25] , and color-coded duplex sonography was performed at discharge and at 1, 3, 6, and 12 months after treatment.
Postprocedural Treatment
During the intervention, all patients received 5000 U of unfractionated heparin intra-arterially; after treatment, intravenous heparin was administered at 1000-1200 U/h for 24 h to achieve an activated partial thromboplastin time of 50 to 70 s. On discharge, a lifetime regimen of oral acetylsalicylic acid (100 mg/day) and an 8-week course of clopidogrel (75 mg/day) were initiated. Oral anticoagulation using phenprocoumon was given only to patients with markedly impaired distal runoff.
Results
During a 12-month period 76 FP CTOs ([10 cm) were treated with endovascular techniques. The initial attempt to cross the occlusion with the CTO guidewire V18 (Boston Scientific) was unsuccessful in 26 of 76 limbs (34.26%). A secondary attempt using the FR-XP (crossover approach, 27%; antegrade, 73%), performed in all 26 failed cases, was successful in 17 limbs (65.38%), raising the overall technical success rate to 88.12%. The main reasons for failure with the FR-XP were inability to cross the proximal cap of the CTO due to heavy calcification (six of nine) (see Fig. 4 ) and inability to re-enter the true lumen after subintimal passage of the occluded segment (three of nine) (see Fig. 5A-C) . Overall the MCG provided sufficient support for crossing the lesion. Subintimal recanalization with the assistance of the Outback LTD Re-entry catheter (Cordis Corp.) was used and was technically successful in 6 of 26 cases. The true lumen was not re-entered in three limbs and these patients were converted to open repair.
The total time required to cross the lesion with Fr-XP manipulation was \8 min, and this was routinely accomplished in\5 min. The overall mean procedural fluoroscopy time was 22.9 min. In two cases prolonged fluoroscopy times, [30 min, were needed for recanalization. Minor complications associated with the Fr-XP included one distal extension of the dissection with involvement of the first Fig. 4 Perforation with the Frontrunner XP CTO Catheter in an occluded SFA segment. Successful recanalization could not be achieved due to heavy calcification. The patient was referred for femoropopliteal bypass 3 days later popliteal segment (1/26; 3.8%) and one perforation in the occluded segment (1/26; 3.8%), both managed interventionally. Immediate procedure-related complications after PTA and stenting were observed in three patients (11.5%) and consisted of distal embolization in two patients (both successfully treated by aspiration thrombectomy and/or short-term local fibrinolysis) and an arteriovenous fistula of the native artery in proximity to the implanted stent in one case. The latter did not require further treatment and resolved before the 24-h follow-up. Major complications requiring further medical, interventional, or surgical measures were not seen.
Discussion
Endovascular therapy of complex peripheral vascular disease remains controversial. Vascular surgery remains an effective treatment option for chronic FP occlusions and is the most appropriate and preferred therapy for many patients. One study on the results of autogenous infrainguinal reconstruction, with 5-year cumulative patency rates for 3005 limbs, demonstrated a 2% operative mortality rate, a 5-year primary patency of 70%, and secondary patency of 81%. Complication rates, however, were not insignificant, with hemorrhage in \2%, graft thrombosis in 2-7%, and wound infection rates ranging between 8 and 19% [2] . Currently, endovascular methods are being used increasingly as the initial approach for treating FP disease, as they have been shown to result in lower morbidity and mortality compared to bypass surgery [26] . Although the recently published midterm success of the newer generation of self-expanding nitinol stents, drug-eluting stents, and expanded polytetrafluoroethylene (PTFE)-covered self-expanding stent-grafts in the SFA has stimulated interest in tackling these long SFA occlusions with an [27] [28] [29] [30] [31] [32] [33] [34] [35] , initially successful passage of long FP arterial occlusions continues to be an endovascular challenge.
During recent years many new technologies and techniques for recanalization of CTOs have been developed. One investigation by Scheinert et al. evaluated 318 consecutive patients in whom the excimer laser-assisted angioplasty technique was used to treat 411 SFAs with occlusions averaging 19.4 cm in length. In that study, the total technical success rate of excimer laser-assisted angioplasty in crossing vessel occlusions was 90.5%. However, to maintain patency and quality of life, additional interventions were required in most patients. At 1 year, the primary and assisted (repeat balloon angioplasty) patency rates were 20.1% and 64.6%, respectively. The secondary patency rate after repeat recanalization procedures was 75.1% [5] . Laird et al. (LACI trial) showed, in a study of 155 limbs in 145 patients with Rutherford class 5 or 6 ischemia, that excimer laser-assisted angioplasty might be a viable treatment strategy for patients with CLI who are not good candidates for bypass surgery [8] . Zeller et al. reported promising results (primary patency rate at 6 months, 73%) using a new-generation percutaneous rotational atherectomy device (Pathway PV) in de novo occlusions and instent restenoses in infragenicular arteries (n = 15). However, the serious adverse event rate at 30 days was 20% in that study [6] . While initial outcomes with the new Silverhawk Atherectomy Catheter (directional atherectomy), which is specifically designed for FP and below-the-knee arteries, seem promising, many questions remain regarding its ultimate role in treating long occlusive SFA disease [12] . What is true for most of the techniques described, however, is that in many cases guidewire passage must be achieved before the devices can be used.
Subintimal recanalization with distal re-entry, known as percutaneous intentional extraluminal recanalization (PIER), has been advocated in recent years as a solution to the problem of unsuccessful pass through multisegmental long calcified occlusions. The Leicester group reported a 90% technical success rate for SFA subintimal angioplasty in a series of patients with a mean occlusion length of 15 cm [15] . This approach, however, has been limited in some cases by the lack of controlled re-entry into the true lumen of the target vessel. Additionally, true lumen reentry using hydrophilic wires and catheters is not achieved until subintimal passage to a site significantly remote from the level of vessel lumen patency, causing subintimal angioplasty or stenting to extend beyond the occluded segment. As to the durability of the subintimally created channels, there is ongoing controversy. There have been only a few studies on the efficacy of subintimal angioplasty in the treatment of very long lesions extending over multiple limb segments. The initially relatively high long-term patency rate reported by Bolia's group has not been reproduced in most series [7, 8, 11, 36] . Although some recent investigations suggest that the technique is effective [37, 38] , there is still no randomized study comparing PIER with intraluminal angioplasty.
The FR-XP, a relatively new device, is designed to improve the technical success of traversing complex peripheral lesions. To date, however, recanalization success with this new device and the impact of the technology are unknown for peripheral arteries, and it has not been tested in large trials or randomized studies. This paper reports a single-center experience with the FR-XP in revascularization of long FP arterial occlusions (TASC B, C, and D lesions). A consecutive series of 26 patients with CTO's of native FP arteries was enrolled after intraluminal guidewire failure. The indications for treatment were severe claudication, pain at rest, and minor trophic changes of the limb. Primary end points of the study were immediate technical and clinical success. Primary success (defined as successfully recanalization with PTA, adjunctive stenting, and \30% residual stenosis) was achieved in 65.38% of patients, raising the overall technical success rate of recanalization in 76 patients with long CTOs of the FP to 88.12%.
The FR-XP (Cordis Corp.) is a blunt microdissection device that takes advantage of the elastic properties of adventitia versus the inelastic properties of fibrocalcific plaque to create fracture planes. This technique may be advantageous in penetrating hard fibrous caps of SFA occlusions. The device separates atherosclerotic plaque in various tissue planes, creating a passage through the CTO. The FR-XP is relatively easy and safe to use, and it may facilitate crossing complex calcified CTOs in the peripheral arteries. Lesion location and length do not seem to significantly influence the success rate with the FR-XP. However, the frequency of complications seemed to be influenced by the extent of calcifications in the treated vessel. In addition to improving the success rate of crossing CTOs, the FR-XP should be considered as an alternative method after guidewire failure. In our experience, the FR-XP has taken a preeminent position in the treatment of long, complex, calcified FP occlusions. Its low complication rate and the reduction of the fluoroscopy time have encouraged us to broaden its applications. The main limiting factor remains its cost. Further evaluation of the technique is necessary to confirm its safety and determine its technical and clinical success.
Limitations
Some limitations of the present study need to be addressed. First, this study included only a small number of patients. Second, this study was not randomized and no matched subintimal (PIER) or retrograde treated occlusions via popliteal access were available for comparison. Third, there was a bias in patient selection since FR-XP recanalization was performed only in patients in whom intraluminal guidewire recanalization failed. However, this bias was unfavorable for the FR-XP group, since it included more difficult cases with longer and older occlusions. Thus, the bias in patient selection does not weaken, but rather strengthens, the results of our study. Despite these important limitations, the results of our study suggest that the use of the FR-XP can be an effective alternative treatment in patients with claudication after guidewire failure.
Conclusion
Our preliminary results using the Fr-XP CTO intraluminal recanalization of chronic total FP occlusions are promising. Although our study sample was small, this approach appears to be a feasible and relatively safe option after failed intraluminal recanalization of CTO of FP arteries with a guidewire. Based on the results of our study, we have made some changes in our treatment algorithm in patients with intermittent and severe claudication. Additional experience is necessary to fully delineate the role of this device in endovascular interventions.
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